238 related articles for article (PubMed ID: 18981952)
1. High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients.
Sanlioglu AD; Dirice E; Elpek O; Korcum AF; Ozdogan M; Suleymanlar I; Balci MK; Griffith TS; Sanlioglu S
Pancreas; 2009 Mar; 38(2):154-60. PubMed ID: 18981952
[TBL] [Abstract][Full Text] [Related]
2. High levels of endogenous tumor necrosis factor-related apoptosis-inducing ligand expression correlate with increased cell death in human pancreas.
Sanlioglu AD; Dirice E; Elpek O; Korcum AF; Balci MK; Omer A; Griffith TS; Sanlioglu S
Pancreas; 2008 May; 36(4):385-93. PubMed ID: 18437085
[TBL] [Abstract][Full Text] [Related]
3. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.
Sanlioglu AD; Korcum AF; Pestereli E; Erdogan G; Karaveli S; Savas B; Griffith TS; Sanlioglu S
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):716-23. PubMed ID: 17512128
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma.
Koksal IT; Sanlioglu AD; Karacay B; Griffith TS; Sanlioglu S
Urol Oncol; 2008; 26(2):158-65. PubMed ID: 18312935
[TBL] [Abstract][Full Text] [Related]
5. Actinin-4 expression in primary and metastasized pancreatic ductal adenocarcinoma.
Welsch T; Keleg S; Bergmann F; Bauer S; Hinz U; Schmidt J
Pancreas; 2009 Nov; 38(8):968-76. PubMed ID: 19672209
[TBL] [Abstract][Full Text] [Related]
6. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma.
Trauzold A; Siegmund D; Schniewind B; Sipos B; Egberts J; Zorenkov D; Emme D; Röder C; Kalthoff H; Wajant H
Oncogene; 2006 Nov; 25(56):7434-9. PubMed ID: 16751802
[TBL] [Abstract][Full Text] [Related]
7. Molecular markers associated with lymph node metastasis in pancreatic ductal adenocarcinoma by genome-wide expression profiling.
Hirono S; Yamaue H; Hoshikawa Y; Ina S; Tani M; Kawai M; Ushijima M; Matsuura M; Saiki Y; Saiura A; Yamamoto J; Miki Y; Noda T
Cancer Sci; 2010 Jan; 101(1):259-66. PubMed ID: 19817750
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
[TBL] [Abstract][Full Text] [Related]
9. Expression of Ezrin and phosphorylated Ezrin (pEzrin) in pancreatic ductal adenocarcinoma.
Cui Y; Li T; Zhang D; Han J
Cancer Invest; 2010 Mar; 28(3):242-7. PubMed ID: 20158339
[TBL] [Abstract][Full Text] [Related]
10. Comparative proteomic analysis for the detection of biomarkers in pancreatic ductal adenocarcinomas.
Qi T; Han J; Cui Y; Zong M; Liu X; Zhu B
J Clin Pathol; 2008 Jan; 61(1):49-58. PubMed ID: 17412869
[TBL] [Abstract][Full Text] [Related]
11. DR5 and DcR2 are expressed in human lumbar intervertebral discs.
Chen B; Ma B; Yang S; Xing X; Gu R; Hu Y
Spine (Phila Pa 1976); 2009 Sep; 34(19):E677-81. PubMed ID: 19730199
[TBL] [Abstract][Full Text] [Related]
12. DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells.
Sanlioglu AD; Karacay B; Koksal IT; Griffith TS; Sanlioglu S
Cancer Gene Ther; 2007 Dec; 14(12):976-84. PubMed ID: 17853923
[TBL] [Abstract][Full Text] [Related]
13. The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma.
Marchesi F; Piemonti L; Fedele G; Destro A; Roncalli M; Albarello L; Doglioni C; Anselmo A; Doni A; Bianchi P; Laghi L; Malesci A; Cervo L; Malosio M; Reni M; Zerbi A; Di Carlo V; Mantovani A; Allavena P
Cancer Res; 2008 Nov; 68(21):9060-9. PubMed ID: 18974152
[TBL] [Abstract][Full Text] [Related]
14. Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells.
Haselmann V; Kurz A; Bertsch U; Hübner S; Olempska-Müller M; Fritsch J; Häsler R; Pickl A; Fritsche H; Annewanter F; Engler C; Fleig B; Bernt A; Röder C; Schmidt H; Gelhaus C; Hauser C; Egberts JH; Heneweer C; Rohde AM; Böger C; Knippschild U; Röcken C; Adam D; Walczak H; Schütze S; Janssen O; Wulczyn FG; Wajant H; Kalthoff H; Trauzold A
Gastroenterology; 2014 Jan; 146(1):278-90. PubMed ID: 24120475
[TBL] [Abstract][Full Text] [Related]
15. Alteration of activity and survival of osteoblasts obtained from human periodontitis patients: role of TRAIL.
Mori G; Brunetti G; Colucci S; Ciccolella F; Coricciati M; Pignataro P; Oranger A; Ballini A; Farronato D; Mastrangelo F; Tetè S; Grassi FR; Grano M
J Biol Regul Homeost Agents; 2007; 21(3-4):105-14. PubMed ID: 18261262
[TBL] [Abstract][Full Text] [Related]
16. EphA4 receptor, overexpressed in pancreatic ductal adenocarcinoma, promotes cancer cell growth.
Iiizumi M; Hosokawa M; Takehara A; Chung S; Nakamura T; Katagiri T; Eguchi H; Ohigashi H; Ishikawa O; Nakamura Y; Nakagawa H
Cancer Sci; 2006 Nov; 97(11):1211-6. PubMed ID: 16965393
[TBL] [Abstract][Full Text] [Related]
17. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.
Mees ST; Mardin WA; Sielker S; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
Ann Surg Oncol; 2009 Aug; 16(8):2339-50. PubMed ID: 19475450
[TBL] [Abstract][Full Text] [Related]
18. Gamma-aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor pi subunit.
Takehara A; Hosokawa M; Eguchi H; Ohigashi H; Ishikawa O; Nakamura Y; Nakagawa H
Cancer Res; 2007 Oct; 67(20):9704-12. PubMed ID: 17942900
[TBL] [Abstract][Full Text] [Related]
19. Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma.
Hwang TL; Liang Y; Chien KY; Yu JS
Proteomics; 2006 Apr; 6(7):2259-72. PubMed ID: 16493704
[TBL] [Abstract][Full Text] [Related]
20. Netrin-1 mediates early events in pancreatic adenocarcinoma progression, acting on tumor and endothelial cells.
Dumartin L; Quemener C; Laklai H; Herbert J; Bicknell R; Bousquet C; Pyronnet S; Castronovo V; Schilling MK; Bikfalvi A; Hagedorn M
Gastroenterology; 2010 Apr; 138(4):1595-606, 1606.e1-8. PubMed ID: 20080097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
